Welcome to the UCL Cancer Institute
The UCL Cancer Institute is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 300 talented scientists who are working together to translate research discoveries into developing better, more effective therapies for cancers and improve outcomes for cancer patients. If you are thinking about postgraduate study with us, applications to our flagship MSc Cancer programme are now open for the academic year 2017/18, or view details of our new funded PhD studentship project examining T cell responses, supervised by Dr Sergio Quezada and Dr Javier Herrero.
Research led by UCL and Queen Mary University of London (QMUL) scientists has identified epigenetic changes in three types of immune cell that could contribute to the development of type 1 diabetes. These changes were only found in patients with diabetes, opening the door to future biomarker development. The study, published today in Nature Communications, employed a unique experimental design that can now allow researchers to more confidently interpret results from epigenomic studies.
Published: Nov 29, 2016 6:45:50 PM
Research published this week in Cell Reports highlights a powerful new data analysis tool that could vastly improve the interpretation of data gathered from epigenomic studies. The scientific team, led by UCL, have developed the eFORGE tool, which offers a new way to identify cell types that underlie complex human disease. The tool can enable researchers to draw more meaningful results from studies on cancer and other diseases, potentially speeding up the process of drug development.
Published: Nov 17, 2016 4:58:31 PM
European epigenomes research project, BLUEPRINT, today announced the release of a collection of 26 publications in Cell, Cell Press-associated and other high-impact journals. The papers are part of a package of 41 publications by the International Human Epigenome Consortium (IHEC) of which BLUEPRINT is a member. Many key papers within the release are authored by Professor Stephan Beck and his scientific team from the Medical Genomics group at UCL Cancer Institute.
Published: Nov 17, 2016 4:57:17 PM
UCL spin-out companies will be at the heart of a new £1 billion life sciences company which has been created by three major investors in cancer research and other biotech fields.
Published: Nov 15, 2016 10:41:03 AM
Support our work
Find out how you can help us to continue research that will lead to breakthroughs in cancer therapies and benefit the lives of cancer patients.